Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine
详细信息 查看全文
- 作者：Suzanne M. Garlanda ; b ; c ; suzanne.garland@thewomens.org.au" class="auth_mail" title="E-mail the corresponding author ; Tak-Hong Cheungd ; Shelly McNeille ; Lone Kjeld Petersenf ; Josefina Romaguerag ; Jorge Vazquez-Narvaezh ; Oliver Bautistai ; Christine Shieldsi ; Scott Vuocoloi ; Alain Luxembourgi
- 关键词：HPV ; Vaccine ; GARDASIL ; Safety ; 9-Valent ; Immunogenicity
- 刊名：Vaccine
- 出版年：2015
- 出版时间：27 November 2015
- 年：2015
- 卷：33
- 期：48
- 页码：6855-6864
- 全文大小：629 K
文摘
- •
V503-006 was a randomized safety and immunogenicity study in females 12–26 years of age.
- •
V503-006 evaluated 9vHPV vaccine in those with previous qHPV vaccination.
- •
9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients.
- •
9vHPV vaccine was immunogenic for HPV 31/33/45/52/58 in prior qHPV vaccine recipients.